Abstract: An electronic gaming machine that includes a display device, a memory device, and a processor. The processor configured to control the display device to display a matrix of symbol positions formed by a plurality of reels and display a first bingo card and a second bingo card wherein the first bingo card includes a first feature indicator and the second bingo card includes a second feature indicator, store in the memory device a first memory structure corresponding to the first bingo card and a second memory structure corresponding to the second bingo card, and in response to determining that a first prize symbol indicator of a first prize symbol displayed in the matrix of symbol positions corresponds to a combination of the first feature indicator and the second feature indicator, populate a position on each of the first bingo card and the second bingo card with the first prize symbol.

Abstract: An electronic gaming machine that includes a display device, a memory device, and a processor. The processor configured to control the display device to display a matrix of symbol positions formed by a plurality of reels and display a first bingo card and a second bingo card wherein the first bingo card includes a first feature indicator and the second bingo card includes a second feature indicator, store in the memory device a first memory structure corresponding to the first bingo card and a second memory structure corresponding to the second bingo card, and in response to determining that a first prize symbol indicator of a first prize symbol displayed in the matrix of symbol positions corresponds to a combination of the first feature indicator and the second feature indicator, populate a position on each of the first bingo card and the second bingo card with the first prize symbol.

Abstract: The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

Abstract: An electronic gaming machine that includes a display device, a memory device, and a processor. The processor configured to control the display device to display a matrix of symbol positions formed by a plurality of reels and display a first bingo card and a second bingo card wherein the first bingo card includes a first feature indicator and the second bingo card includes a second feature indicator, store in the memory device a first memory structure corresponding to the first bingo card and a second memory structure corresponding to the second bingo card, and in response to determining that a first prize symbol indicator of a first prize symbol displayed in the matrix of symbol positions corresponds to a combination of the first feature indicator and the second feature indicator, populate a position on each of the first bingo card and the second bingo card with the first prize symbol.

Abstract: An electronic gaming machine that includes a display device, a memory device, and a processor. The processor configured to control the display device to display a matrix of symbol positions formed by a plurality of reels and display a first bingo card and a second bingo card wherein the first bingo card includes a first feature indicator and the second bingo card includes a second feature indicator, store in the memory device a first memory structure corresponding to the first bingo card and a second memory structure corresponding to the second bingo card, and in response to determining that a first prize symbol indicator of a first prize symbol displayed in the matrix of symbol positions corresponds to a combination of the first feature indicator and the second feature indicator, populate a position on each of the first bingo card and the second bingo card with the first prize symbol.

Abstract: The present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, e.g., an anti-PD-1 antibody or antigen binding fragment thereof (e.g. pembrolizumab), in specific amounts to the patient about every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

Abstract: The present invention relates to methods for treating cancer comprising administering an antagonist of PD-1, e.g., anti-PD-1 antibody or antigen binding fragment thereof, and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the CTLA4 antibody or antigen binding fragment thereof is given at a fixed dose. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody and a dosage of an anti-CTLA4 antibody, and uses thereof.

Abstract: An electronic gaming machine that includes a display device, a memory device, and a processor. The processor configured to control the display device to display a matrix of symbol positions formed by a plurality of reels and display a first bingo card and a second bingo card wherein the first bingo card includes a first feature indicator and the second bingo card includes a second feature indicator, store in the memory device a first memory structure corresponding to the first bingo card and a second memory structure corresponding to the second bingo card, and in response to determining that a first prize symbol indicator of a first prize symbol displayed in the matrix of symbol positions corresponds to a combination of the first feature indicator and the second feature indicator, populate a position on each of the first bingo card and the second bingo card with the first prize symbol.

Abstract: The present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, e.g., an anti-PD-1 antibody or antigen binding fragment thereof (e.g. pembrolizumab), in specific amounts to the patient about every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

Abstract: The present invention relates to methods for treating cancer in a patient comprising administering an anti-PD-1 antibody or antigen binding fragment thereof in specific amounts to the patient about every six weeks, in combination with administering an anti-CTLA4 antibody to the patient about every six weeks. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and a dosage of an anti-CTLA4 antibody or antigen-binding fragment thereof, and uses thereof for treating cancer.

Abstract: The present invention relates to method for treating cancer comprising administering an antagonist of PD-1, e.g., anti-PD-1 antibody or antigen binding fragment thereof, and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the CTLA4 antibody or antigen binding fragment thereof is given at a fixed dose. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody and a dosage of an anti-CTLA4 antibody, and uses thereof.